NeuCyte

5 articles about NeuCyte

• NeuCyte and Mount Sinai Enter Collaboration Agreement

  1/19/2021

  NeuCyte, Inc. , an innovative biotech company focused on developing novel treatments for neurological disorders, today announced that it has entered into a research collaboration agreement with the Seaver Autism Center for Research and Treatment  at the Icahn School of Medicine at Mount Sinai. The Seaver Center is collabor

• NeuCyte and REPROCELL enter distribution agreement in North America and Europe

  9/25/2019

  This new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons (iNs), supplied with astroglia, media and supplements.

• NeuCyte Licenses Promising Novel Compound for Treatment of Refractory Epilepsy and Related Neurological Disorders

  9/24/2019

  NeuCyte, Inc., an innovative biotech company focused on developing novel treatments for neurological disorders, today announced that it has entered into an exclusive license agreement with Trillium Therapeutics to advance an undisclosed preclinical compound with potential utility in treating refractory epilepsy in the form of Dravet syndrome and related disorders.

• NeuCyte Licenses Its Novel Neuronal Programming Technology to Enable Academic Research

  12/3/2018

  The hospital intends to use this technology for internal research, teaching and educational purposes, and to perform services to other academic institutions.

• NeuCyte Inc. Closes $6.7 Million Series A Financing

  5/8/2018

  SUNNYVALE, Calif., May 8, 2018 /PRNewswire/ -- NeuCyte, Inc., a leading neuroscience drug discovery company, announced the closing of a Series A financing round of $6.7 million, for a totaled funding of more than $8 million. NeuCyte's initial investors, Cowin Venture and Leaguer Ventures, led the round.